One of the most useful meeting points between Ayurveda and modern medicine is personalized response. Ayurveda approaches the patient through prakriti, agni, bala, age, season, disease state, formulation, dose, and anupana rather than through a single uniform rule. Modern pharmacogenomics approaches the same problem from another direction: genetic variation in drug-metabolizing enzymes and transport pathways can make a standard drug dose suitable for one person and unsuitable for another.

The central question is not whether classical Ayurveda predicted modern enzyme names such as CYP2C19. It did not use that language. The useful question is narrower and more rigorous: do carefully assessed vata, pitta, and kapha constitutional patterns correlate with measurable biological differences that may influence absorption, metabolism, response, or adverse effects?

The Classical Foundation: Prakriti, Agni, and the Patient Context

In classical Ayurvedic reasoning, medicines are not prescribed only by disease name. Charaka’s Vimana Sthana places prakriti among the clinical factors to be considered before treatment, together with the patient’s strength, the strength of disease, digestive capacity, drug potency, season, and other circumstances. This makes prakriti part of a wider rogi-pariksha framework rather than a stand-alone dosing shortcut.

Agni is the Ayurvedic language for digestive and metabolic capacity. The classical agni vocabulary includes balanced, sharp, weak, and irregular patterns. When prakriti is assessed clinically, these digestive tendencies are read together with body build, appetite, thirst, bowel habit, tolerance to heat or cold, tissue strength, and behavioral features. In modern prakriti-genomics publications, the same clinical traits are often used to identify constitutionally extreme groups for biological comparison.

• Vata-predominant constitution: commonly described with lighter build, dryness, quickness, irregular appetite, irregular bowel habit, and variable tolerance. In a pharmacological context, this supports careful observation of absorption, tolerance, and day-to-day variability rather than a fixed dose assumption.
• Pitta-predominant constitution: commonly described with moderate build, stronger appetite and thirst, good digestive power, heat tendency, and sharper metabolic expression. This is the constitution that has most often been compared with “faster” metabolic language in prakriti-genomics discussions.
• Kapha-predominant constitution: commonly described with broader build, steadiness, tendency toward weight gain, lower appetite, slower digestion, and greater structural stability. In dosing discussions, this supports attention to heaviness, sedation, digestive tolerance, and accumulation-like clinical patterns, while still requiring drug-specific judgment.

Modern Publications: Prakriti, Genes, and Metabolic Markers

Several peer-reviewed papers have examined whether Ayurvedic prakriti groups differ in measurable biological markers. The strongest available work is association-based: it compares prakriti groups with gene expression, biochemical markers, SNP patterns, CYP2C19 genotype distribution, DNA methylation patterns, and microbiome signatures. These publications are useful for hypothesis-building, but they do not justify changing modern prescription doses without approved pharmacogenomic guidance and clinical supervision.

Prasher et al. 2008: Gene Expression and Biochemical Differences

A Journal of Translational Medicine paper by Prasher, Mukerji, and collaborators examined healthy individuals classified into constitutionally extreme vata, pitta, and kapha groups. The final analyzed group included 96 unrelated healthy individuals of Indo-European ancestry, assessed through an Ayurvedic questionnaire and physician evaluation. The paper reported differences across prakriti groups in biochemical and hematological parameters and genome-wide expression patterns, including lipid-related differences in kapha males and hematological differences in pitta males.

This paper is important because it did not reduce prakriti to a single enzyme. It treated prakriti as a phenotype involving multiple physiological dimensions. It also described characteristic clinical features used in prakriti assessment: vata subjects had irregular appetite and bowel patterns, pitta subjects had high appetite and good digestive power, and kapha subjects had lower appetite, lower digestion, broader build, and tendency to gain weight.

Ghodke et al. 2011: Prakriti and CYP2C19 Genotype

The clearest publication linking prakriti with a specific drug-metabolizing enzyme is the CYP2C19 paper by Ghodke and colleagues in Evidence-Based Complementary and Alternative Medicine. It genotyped CYP2C19 in 132 unrelated healthy subjects and reported a significant association between major prakriti types and CYP2C19 genotype distribution.

In that cohort, extensive metabolizer genotypes were more frequent among pitta-predominant individuals, while poor metabolizer genotypes were more frequent among kapha-predominant individuals. The paper reported that the poor metabolizer genotype group was highest in kapha and that one poor-metabolizer genotype pattern showed significant association with kapha. This supports a cautious prakriti-pharmacogenomics connection for CYP2C19, not a universal rule for all drug metabolism.

Govindaraj et al. 2015: TRISUTRA Genome-Wide Analysis

The TRISUTRA-associated Scientific Reports paper by Govindaraj and colleagues expanded the scale of prakriti-genomics work. It screened 3,416 healthy young males and selected 262 well-classified subjects after physician assessment and AyuSoft-supported classification. The study used genome-wide SNP analysis and reported 52 SNPs with significant distribution differences among prakriti groups.

A key corrected point is the PGM1 association: the paper linked a PGM1 variant with pitta prakriti, not kapha prakriti. PGM1 is involved in carbohydrate and energy metabolism, which fits the paper’s discussion of pitta as a metabolism-linked constitutional pattern. The study also emphasized that the selected prakriti groups were not simply separated by broad population genetic stratification.

Epigenetic and Microbiome Extensions

Later work extended the prakriti question beyond SNPs and CYP2C19. Rotti and colleagues described prakriti-specific DNA methylation signatures in stratified Indian subjects, with pitta, vata, and kapha groups showing distinct methylation patterns. Microbiome-focused publications have also treated prakriti as a possible stratifier of gut microbial variation, including reports that some bacterial genera may be enriched in certain prakriti groups in Indian cohorts.

These areas are relevant to pharmacokinetics because methylation can influence gene expression, and the gut microbiome can affect digestion, inflammation, bile acid handling, and microbial metabolism of some compounds. They remain exploratory for dosing decisions, but they strengthen the broader view that prakriti may capture multi-layered biological variation.

Mapping Prakriti to Pharmacogenomic Phenotypes

The most responsible way to map prakriti to pharmacogenomics is to keep the mapping narrow and drug-specific. CYP2C19 is relevant for medicines such as proton-pump inhibitors and clopidogrel, but the clinical meaning of a faster or slower CYP2C19 phenotype depends on whether the medicine is being activated, inactivated, or otherwise modified by that pathway.

Clinical Implications: What This Means in Practice

The practical message is not that prakriti can replace genotype testing. The practical message is that prakriti may add a clinically observable layer to individualized care, especially in Ayurveda, integrative practice, and early-stage pharmacogenomic screening work. It should be used as context, not as an independent authority to change prescription doses.

For Ayurvedic Prescribing

Ayurvedic prescribing already includes more than the botanical name. A practitioner considers the patient’s prakriti, vikriti, agni, strength, age, season, formulation strength, dose, timing, diet, and anupana. In that setting, prakriti helps determine whether a formulation should be given gently, sharply, with warming support, with cooling support, in divided doses, or with close follow-up.

• Pitta-predominant patients may need attention to heat, acidity, loose stools, irritability, and intolerance to overly sharp or heating preparations. Their stronger digestive profile does not automatically mean higher dosing; the herb, formulation, disease state, and season still matter.
• Kapha-predominant patients may need attention to sluggish digestion, heaviness, sleepiness, edema tendency, and tolerance of heavier formulations. Classical use of suitable anupana and diet becomes especially important in this group.
• Vata-predominant patients may need smaller steps, steadier routines, warm anupana, attention to dryness and constipation, and more frequent follow-up when beginning a new formulation.

For more on how carrier substances modify herbal delivery and tolerability, see The Science of Anupana.

For Conventional Medicine

In conventional prescribing, prakriti assessment should not replace pharmacogenomic testing, renal and hepatic assessment, drug-interaction review, therapeutic drug monitoring, or approved clinical algorithms. Where CYP2C19 is clinically relevant, the meaning of the phenotype differs by medicine. For proton-pump inhibitors, CYP2C19 can influence exposure and response. For clopidogrel, CYP2C19 is needed for metabolic activation, so reduced-function alleles can reduce antiplatelet effect.

A validated prakriti assessment could become a low-cost preliminary phenotyping tool in future research or resource-limited settings, but current drug decisions should remain anchored in approved guidelines, patient history, medication list, laboratory data, and clinician judgment.

Limitations and Cautious Interpretation

The prakriti-pharmacogenomics connection is promising but early. The available publications are best read as association work that helps frame future personalized-medicine questions. They are not yet a dosing system for modern prescriptions.

Sample Size and Cohort Design

The main human cohorts remain modest by pharmacogenomic standards: 96 subjects in the Prasher paper, 132 subjects in the Ghodke CYP2C19 paper, and 262 selected male subjects in the Govindaraj genome-wide paper. These sample sizes can detect useful signals, but larger, multi-center, independently replicated cohorts are needed for clinical translation.

Prakriti Classification Variability

Prakriti assessment methods vary across studies. Some use physician assessment, some use questionnaires, some use software support, and some combine methods. A 2025 review identified 64 unique prakriti assessment tools from 1987 to 2024, with only 20 undergoing any validation and only CCRAS-PAS software and the ACPI scale meeting seven of nine recommended development-and-validation criteria. This means future pharmacogenomic work needs more standardized prakriti classification.

Population and Generalizability

Most published prakriti-genomics work has been conducted in Indian populations, and some cohorts focused on young healthy males. CYP allele frequencies vary by ancestry, region, and population history. A prakriti association observed in one Indian cohort should not be assumed to apply unchanged to every ethnic group or clinical population.

Drug-Specificity

“Fast metabolizer” and “slow metabolizer” are not universal clinical labels. A person may be fast for one enzyme pathway and normal or slow for another. A drug may be inactivated by an enzyme, activated by it, transported by another system, or affected more by kidney function than liver metabolism. Prakriti should therefore be treated as a broad constitutional phenotype, not as a direct substitute for enzyme-specific pharmacogenomics.

Emerging Research Directions

The next phase should move from broad correlation to clinically testable models. The strongest future work would combine standardized prakriti assessment with genotype, transcriptomic, methylation, microbiome, metabolomic, diet, sex, age, ancestry, liver function, kidney function, and actual drug-exposure data.

Practical Applications Today

Current practice should treat prakriti as a useful constitutional lens, not as a stand-alone dosing calculator. It can guide observation, formulation choice, anupana, diet, follow-up frequency, and tolerance monitoring, while modern prescription decisions remain governed by standard medical care.

• Use prakriti for context: note constitution, agni, bowel pattern, appetite, heat or cold tendency, sleep, body build, and sensitivity before beginning herbs or medicines.
• Use pharmacogenomic testing where indicated: when a drug has clinically recognized CYP2C19 guidance, genotype-based recommendations are more specific than prakriti inference.
• Track response carefully: observe benefit, adverse effects, digestion, sleep, stool pattern, sedation, acidity, bleeding risk, and other drug-specific warning signs.
• Avoid self-adjusting medication: do not raise, lower, stop, or combine prescription medicines based on self-assessed prakriti.

For a structured introduction to constitution assessment, see Doshic Assessment at Home.

The Broader Significance

The convergence of prakriti and pharmacogenomics is meaningful because both frameworks recognize individual variation. Ayurveda arrived at personalization through long clinical observation of constitution, digestion, strength, season, and response. Pharmacogenomics approaches personalization through genes, enzymes, transporters, and drug-specific pathways.

The most balanced position is neither to claim that ancient texts named modern enzymes nor to dismiss prakriti as irrelevant. The better path is careful translation: use classical categories with fidelity, use modern methods with precision, and test clinically useful links without exaggeration.

Medical Disclaimer: This article is for educational purposes only. Drug dosing decisions should always be made by qualified healthcare providers based on approved clinical guidelines, patient history, laboratory findings, medication list, and, where appropriate, pharmacogenomic testing. Do not modify medication doses based on self-assessed prakriti without consulting your prescribing physician.

Nothing in this article diagnoses or treats a medical condition. Consult a qualified Ayurvedic practitioner or licensed healthcare provider before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a medical condition, scheduled for surgery, or taking prescription medication.

References

1. Charaka Samhita — Rogabhishagjitiya Vimana
2. Charaka Samhita — Deha prakriti
3. Translational-medicine (translational-medicine.biomedcentral.com)
4. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda (2008), PubMed
5. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda (2008), PubMed
6. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
7. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
8. Nature (nature.com)
9. Genome-wide analysis correlates Ayurveda Prakriti (2015), PubMed
10. DNA methylation analysis of phenotype specific stratified Indian population (2015), PubMed
11. DNA methylation analysis of phenotype specific stratified Indian population (2015), PubMed
12. Researcher (researcher.manipal.edu)
13. MedlinePlus
14. Files (files.cpicpgx.org)
15. Files (files.cpicpgx.org)
16. Frontiersin (frontiersin.org)

Pharmacogenomics studies how a person’s DNA can influence medication response, including differences in drug metabolism, therapeutic effect, adverse reactions, and dose requirements. From an Ayurvedic perspective, its closest point of contact is deha prakriti, the constitutional assessment of an individual through stable physical, physiological, and psychological tendencies.

The most useful way to frame the intersection is not to equate a dosha directly with a gene. Rather, prakriti can be understood as a structured phenotypic classification that may help stratify people into biologically meaningful groups. Published work in ayurgenomics has explored whether Vata, Pitta, and Kapha-predominant individuals differ in gene expression, CYP2C19 polymorphisms, DNA methylation, HLA markers, and genome-wide SNP patterns. The clinical promise is personalization; the clinical caution is that prakriti assessment is not a substitute for formal pharmacogenomic testing or medical judgment.

The Foundational Hypothesis: Prakriti as a Phenotypic Framework

Classical Ayurveda describes prakriti as the natural constitution of a person, shaped by dosha predominance and expressed through anatomical build, appetite, digestion, bowel pattern, skin and hair features, heat or cold tolerance, sleep, activity, temperament, disease resistance, and other long-term traits. The classical framework includes seven prakriti categories: Vata, Pitta, Kapha, Vata-Pitta, Vata-Kapha, Pitta-Kapha, and balanced samadoshaja prakriti.

Ayurvedic texts place the formation of constitution at the beginning of life, using ideas such as the union of paternal and maternal reproductive factors, the condition of the uterus, time, maternal diet and lifestyle, and the predominance of dosha. This makes prakriti broader than genotype alone: it is closer to a constitutional phenotype that includes inherited, developmental, metabolic, and behavioral expression.

Published Human Studies Connecting Prakriti and Molecular Variation

The strongest material for this topic comes from small but influential human studies that used prakriti classification as a stratification method. These papers are best read as early translational research: they help define questions for personalized medicine, but they do not create a clinical dosing system.

Prasher et al. (2008): Gene Expression and Biochemical Correlates

Prasher and colleagues published “Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda” in the Journal of Translational Medicine. The study screened volunteers through prakriti assessment and selected 96 unrelated, ethnically matched healthy individuals classified as Vata, Pitta, or Kapha predominant. The work compared biochemical, hematological, and genome-wide expression patterns among these groups.

• The study selected 39 Vata, 29 Pitta, and 28 Kapha individuals after broader screening.
• The authors reported prakriti-linked differences in biochemical and hematological parameters.
• They reported 159 differentially expressed annotated genes in males and 92 in females, with limited overlap between the sex-stratified gene sets.
• The functional categories included transport, immune response, regulation of blood coagulation, and regulation of cyclin-dependent protein kinase activity.
• The study described itself as an early attempt to connect Ayurvedic phenotyping with modern biological measures.

This paper remains important because it treated prakriti as a reproducible phenotype rather than as a loose descriptive label. Its value for pharmacogenomics is indirect: it suggests that constitutional grouping may capture molecular differences relevant to metabolism and immune response, while leaving drug-specific decisions to future validation.

Ghodke, Joshi and Patwardhan (2011): CYP2C19 and Metabolic Variability

Ghodke, Joshi and Patwardhan examined CYP2C19 polymorphisms in 132 unrelated healthy subjects classified by prakriti. CYP2C19 is a clinically relevant drug-metabolizing enzyme, and the study directly addressed the Ayurvedic idea that Pitta and Kapha differ in metabolic tendency.

• The authors genotyped CYP2C19 using PCR-RFLP.
• The extensive-metabolizer genotype was reported as predominant in Pitta, with 91% of Pitta individuals in that category.
• The poor-metabolizer genotype was reported as highest in Kapha, at 31%, compared with 12% in Vata and 9% in Pitta.
• The CYP2C19 *2/*3 poor-metabolizer genotype was significantly associated with Kapha in the study population.

This is the most directly pharmacogenomic paper in the prakriti literature. It supports a focused research question: whether standardized prakriti assessment can enrich or stratify cohorts for CYP-related variability. It does not make prakriti a replacement for CYP2C19 genotyping when a medication decision requires pharmacogenomic evidence.

Rotti et al. (2015): DNA Methylation Signatures

Rotti and colleagues examined DNA methylation in phenotype-stratified Indian subjects. After a larger prakriti assessment process, the study analyzed 147 healthy male individuals aged 20–30 years who were classified into Vata, Pitta, or Kapha groups.

• The authors reported differentially methylated regions in CpG islands, CpG shores, promoters, untranslated regions, and gene bodies.
• Pitta showed distinct promoter and gene-body methylation signals.
• Vata and Kapha groups also showed prakriti-associated methylation patterns.
• The study validated selected genes including LHX1 for Vata, SOX11 for Pitta, and CDH22 for Kapha.
• CDH22 was discussed in relation to BMI in the Kapha group.

This work adds an epigenomic layer to the ayurgenomics discussion. It is especially relevant because prakriti is described in Ayurveda as a stable constitutional pattern, while methylation reflects regulation of gene expression rather than only fixed DNA sequence.

Govindaraj et al. (2015): Genome-Wide SNP Analysis and PGM1

Govindaraj and colleagues published a genome-wide SNP analysis correlating Ayurveda prakriti in Scientific Reports. The study began with 3,416 assessed individuals and used 262 well-classified male subjects for genome-wide analysis with Affymetrix 6.0 arrays.

• The authors used genome-wide SNP data to examine differences among Vata, Pitta, and Kapha groups.
• They reported 52 markers for genotype-phenotype correlation and 28 genic SNPs among the relevant markers.
• A notable association was reported between Pitta prakriti and PGM1.
• PGM1 is involved in metabolic pathways such as glycolysis, gluconeogenesis, galactose metabolism, purine metabolism, and starch and sucrose metabolism.

The PGM1 finding is meaningful because Pitta is classically linked with digestion, transformation, heat, and metabolism. The proper interpretation is a biologically plausible correlation within a defined study design, not a universal genetic definition of Pitta.

Clinical Implications: A Research Bridge, Not a Stand-Alone Dosing System

The practical attraction of prakriti-guided personalization is clear: Ayurveda already uses constitutional assessment to individualize diet, lifestyle, herbs, therapies, and preventive guidance. Pharmacogenomics similarly seeks to individualize care by identifying genetic variation that affects medication response. The responsible bridge between the two is to use prakriti as a phenotyping layer that may help generate, refine, or test personalized-medicine hypotheses.

In routine medical care, however, medication decisions must not be made from prakriti alone. CYP2C19, for example, is relevant to medicines such as proton pump inhibitors, clopidogrel, and some antidepressants, but clinical interpretation depends on the specific drug, the patient’s genotype, diagnosis, age, organ function, other medicines, treatment goal, and prescribing guidance. Prakriti may eventually help identify who should be prioritized for formal testing or closer monitoring, but the current role is supportive and investigational.

How Prakriti Could Assist Personalization

A careful prakriti-informed model would keep Ayurvedic constitution and modern pharmacogenomics in their proper domains. Prakriti can organize whole-person traits, while pharmacogenomic testing can identify specific genetic variants relevant to particular drugs.

A Prakriti-Informed Research Framework

The most rigorous path is to test prakriti alongside established clinical and genomic variables instead of treating it as a replacement for them. A future study design could combine standardized prakriti assessment, blinded practitioner evaluation, ancestry and demographic data, diet and lifestyle records, laboratory measures, pharmacogenomic panels, and prospective treatment outcomes.

• Use validated prakriti questionnaires and independent clinician assessment to reduce classification error.
• Record age, sex, ancestry, region, diet, disease status, organ function, and concurrent medicines.
• Genotype clinically relevant pharmacogenomic markers, including CYP enzymes where appropriate.
• Follow medication response, adverse effects, dose adjustments, and treatment outcomes prospectively.
• Measure whether prakriti adds predictive value beyond standard pharmacogenomic and clinical variables.

This framework preserves the Ayurvedic insight that patients differ constitutionally while respecting the modern requirement that drug-specific decisions need drug-specific evidence.

Limitations and Necessary Caution

The prakriti-genomics field is intellectually important, but the current human literature is still early-stage. Its findings are best used to shape further research and not to create simplified rules such as “Vata needs one dose,” “Pitta needs another,” or “Kapha needs a higher dose.”

• Sample size: The major studies used carefully selected cohorts such as 96 subjects, 132 subjects, 147 male subjects, or 262 male subjects. These are valuable for hypothesis formation, but not enough for broad clinical rules.
• Population specificity: Several cohorts were drawn from specific Indian populations and may not generalize to every region, ancestry group, age group, or mixed-prakriti population.
• Classification complexity: Prakriti assessment includes many traits and can vary by tool, practitioner, and the dominance of single or mixed dosha patterns.
• Probabilistic associations: A group-level association does not determine an individual person’s CYP status, adverse-effect risk, or medication response.
• Holistic versus single-gene mapping: Prakriti is a multi-dimensional constitutional framework, while pharmacogenomic markers are often drug- and pathway-specific.

These limitations do not weaken the value of the research direction; they define the discipline needed to move from correlation to clinical usefulness.

The Path Forward

Ayurgenomics can mature by combining classical Ayurvedic phenotyping with modern study design. The strongest future work would be multi-center, adequately powered, transparent in prakriti classification, and linked to real clinical outcomes rather than only molecular differences.

• Large multi-region cohorts across diverse Indian and global populations.
• Standardized prakriti tools with reproducibility testing between practitioners and questionnaires.
• Integrated omics work combining genomics, transcriptomics, epigenomics, metabolomics, microbiome data, and clinical parameters.
• Prospective medication-response studies for specific drugs with known pharmacogenomic relevance.
• Independent replication before any prakriti-based medication guidance is used in routine care.

The meeting point of Ayurveda and pharmacogenomics is not a shortcut around modern testing; it is a possible enrichment of personalized medicine through a deep constitutional phenotype. If validated at scale, prakriti may help clinicians and researchers think about individuality in a more integrated way. For related reading, see Reverse Pharmacology in Ayurveda and Ayurvedic Herbs and Cytochrome P450 Enzymes.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Do not start, stop, reduce, increase, or substitute any medication based on prakriti, dosha assessment, CYP status, or online information alone. Consult a licensed physician, clinical pharmacologist, qualified Ayurvedic practitioner, or other qualified healthcare provider for individualized care. Formal pharmacogenomic testing, when needed, should be ordered and interpreted by qualified professionals in the context of the specific medicine and patient.

References

1. Genome (genome.gov)
2. MedlinePlus
3. FDA
4. Charaka Samhita — Deha prakriti
5. Charaka Samhita — Khuddika Garbhavakranti Sharira
6. Link (link.springer.com)
7. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda (2008), PubMed
8. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
9. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts (2012), PubMed
10. DNA methylation analysis of phenotype specific stratified Indian population (2015), PubMed
11. Association between depressive symptoms, weight and treatment outcome in a very large anorexia nervosa sample (2016), PubMed
12. Nature (nature.com)
13. Genomicseducation (genomicseducation.hee.nhs.uk)

This review keeps the article’s focus on a cautious, research-oriented assessment of the field. AI can help organise observable features and questionnaire responses, but Prakriti in Ayurveda is a lifelong constitutional pattern, not a single photograph, a pulse waveform, or an app score. The safest interpretation is to treat automated assessment as structured decision support, not as a replacement for trained Ayurvedic clinical judgement.

What Is Prakriti and Why Is It Hard to Assess?

Prakriti, often translated as constitutional type, describes the individual’s inherent pattern of physical, physiological, behavioural, and mental traits. Classical Ayurveda explains Deha Prakriti through the relative predominance of Vata, Pitta, and Kapha, with seven dosha-based patterns: Vata, Pitta, Kapha, Vata-Pitta, Vata-Kapha, Pitta-Kapha, and Sama or balanced Prakriti. Charaka Samhita describes these constitutional patterns in Vimana Sthana, and Sushruta Samhita explains Prakriti in relation to the predominance of dosha at the time of conception.

Prakriti is difficult to assess because no single sign is decisive. A proper assessment draws from repeated patterns in body build, appetite, digestion, sleep, temperature tolerance, skin and hair qualities, mental tendencies, pace of speech and action, emotional response, stamina, and adaptation to season and stress. Classical clinical assessment is not merely a checklist; it depends on observation, questioning, touch, and interpretation of the person’s overall pattern.

The major challenge for modern research is standardisation. Questionnaires, physician assessments, software tools, image-based models, and device-based methods do not always define or weight the same features in the same way. Inter-rater differences among practitioners and differences between questionnaire instruments can affect the label used as the “ground truth” for machine learning. This matters because an algorithm trained on inconsistent labels will reproduce that inconsistency more efficiently, not solve it.

Machine Learning Approaches: What Has Been Tried

AI-based Prakriti assessment has mainly developed through three routes: structured questionnaires and phenotypic traits, computer-vision analysis of visible features, and device-linked or multimodal systems. Each route can improve documentation and repeatability, but each also depends heavily on the quality of the original Prakriti labels and the population used to build the model.

Questionnaire and Phenotypic-Trait Models

One of the clearest machine-learning examples is the 2017 PLOS One work on recapitulating Ayurveda constitution types from phenotypic traits. The study used data from 147 healthy individuals with extreme Vata, Pitta, or Kapha Prakriti and applied methods such as LASSO, elastic net, and random forest models. The work showed that machine learning can classify carefully selected extreme constitution types from structured phenotypic features and can reduce the number of features needed for classification.

This kind of model is valuable for formalising what is otherwise a complex clinical judgement. Its limitation is that extreme single-dosha groups are easier to classify than mixed constitutions, and healthy research volunteers are not the same as people presenting with active illness, seasonal imbalance, medication use, stress, poor sleep, or overlapping Vikriti. In practical terms, questionnaire-based AI is strongest when used to structure assessment, flag patterns, and support research stratification rather than to make final clinical decisions by itself.

Computer Vision: Tongue, Face, and Skin Features

Computer-vision approaches have explored tongue images, facial features, eye and mouth ratios, nose-related measurements, and skin-colour features. A 2020 pilot study used tongue-image features and machine-learning classifiers to identify dosha patterns, while a 2024 facial-feature study used face, eye, nose, mouth, and skin-colour attributes in a small image dataset. A 2025 skin-colour classification paper also explored image processing with machine-learning methods for Prakriti-related classification.

These systems are interesting because they convert visible clinical observations into measurable inputs. Their limitations are equally important: lighting, camera quality, pose, distance, skin tone, local environment, image preprocessing, small datasets, and label quality can all change model performance. Tongue and facial analysis may assist documentation, but they should not be treated as a complete Prakriti assessment without broader clinical context.

Device-Linked and Multimodal Directions

Recent reviews describe Prakriti tools across questionnaires, algorithms, machine-learning systems, and devices. The direction of travel is toward combining multiple inputs: questionnaire responses, body measurements, pulse-related signals, tongue images, photoplethysmography, electrocardiography, and other physiological markers. This multimodal approach fits Ayurveda better than single-feature classification because Prakriti itself is multidimensional.

The most promising use of multimodal systems is not instant diagnosis but better record-keeping, repeatable feature capture, and transparent comparison between practitioner judgement and structured data. For a clinical system to be trustworthy, it needs clear population details, an explicit labelling method, repeat testing, external validation, and careful distinction between Prakriti and Vikriti.

Genomic and Biological Validation: What It Does and Does Not Prove

Genomic and molecular work has made Prakriti a serious subject for systems-biology discussion. A 2008 Journal of Translational Medicine study examined genome-wide expression and biochemical correlates among extreme constitutional types. A 2015 Scientific Reports genome-wide analysis screened thousands of healthy male volunteers, used physician assessment together with AyuSoft confirmation, and selected a smaller subset for SNP analysis across Vata, Pitta, and Kapha groups.

This work supports the idea that carefully assessed Prakriti can be studied alongside biological variables. It does not mean that every AI tool, app, photograph model, or questionnaire score has biological validity. Genomic work can strengthen the rationale for careful phenotyping, but an AI model still needs its own validation against reliable labels, diverse populations, and clinically meaningful outcomes.

Critical Limitations

Several limitations must be kept visible before AI Prakriti assessment is used in clinical practice. These limitations are not minor technical details; they directly affect whether the output represents constitutional Prakriti or merely a temporary pattern in the available data.

Ground-truth uncertainty: The most important issue is the quality of the original label. If the reference label comes from a weak questionnaire, a single hurried assessment, or a non-standard method, the machine can only learn that weakness. Stronger studies need expert-panel review, transparent assessment criteria, and repeatability testing.

Vikriti conflation: Prakriti is the constitutional baseline, while Vikriti is the current imbalance. Tongue appearance, skin changes, sleep, appetite, pulse qualities, energy, and mood can shift with diet, illness, climate, stress, medication, and routine. A model that does not control for current imbalance may classify the present state rather than the lifelong constitution.

Population bias: Many available datasets are small and drawn largely from Indian or South Asian populations. Models developed in one region, language, climate, diet pattern, or skin-tone range may not perform the same way in another. Global use requires external validation across diverse groups.

Mixed constitution complexity: Classical Ayurveda recognises seven dosha-based constitutional patterns, and contemporary tools sometimes use even more subdivisions. Many machine-learning projects focus on the three extreme single-dosha groups because they are easier to separate. Mixed Prakriti types are more clinically common and harder to classify reliably.

Missing qualitative context: Prakriti assessment includes behavioural rhythm, emotional response, interpersonal style, digestion over time, seasonal response, and long-term tendencies. A photograph or short questionnaire may capture fragments of this picture, but the experienced clinician integrates the person’s history, observation, present health state, and changing context.

What This Means for Clinical Practice

AI Prakriti tools are best understood as aids for structure and consistency. They can help collect information, reduce missing data, document visible features, and support research classification. They should not be used as the sole basis for prescribing herbs, Panchakarma, diet restrictions, Rasayana therapy, or disease treatment.

The most balanced conclusion is that AI Prakriti assessment is useful for improving consistency, documentation, and research design, but it remains a complement to clinical Ayurveda. A trained practitioner considers Prakriti together with Vikriti, Agni, Bala, age, season, diet, sleep, medications, disease state, and the patient’s lived context. No current automated system should replace that clinical synthesis.

For readers interested in how constitutional assessment connects with biological markers, the metabolomics and Ayurveda validation article provides a related foundation. The central point remains the same: biological and digital tools can support Ayurveda only when they are used with clear limits, careful interpretation, and respect for the classical framework.

References and Further Reading

The following references provide the verified foundation for this review and replace unsourced claims about large unpublished AI accuracy studies, commercial app performance, or automatic diagnosis from a single image.

• Charaka Samhita Online. Deha Prakriti and the seven dosha-based constitutional patterns.
• Sushruta Samhita, Sharira Sthana, Chapter 4. Description of Prakriti in relation to dosha predominance at conception.
• Tiwari P, Kutum R, Sethi T, et al. Recapitulation of Ayurveda constitution types by machine learning of phenotypic traits. PLOS One. 2017.
• Prasher B, Negi S, Aggarwal S, et al. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda. Journal of Translational Medicine. 2008.
• Govindaraj P, Nizamuddin S, Sharath A, et al. Genome-wide analysis correlates Ayurveda Prakriti. Scientific Reports. 2015.
• Kurande VH, Bilgrau AE, Waagepetersen R, Toft E, Prasad R. Reliability studies of diagnostic methods in Indian traditional Ayurveda medicine: an overview. 2013.
• Joshi M, et al. Computerized pragmatic assessment of Prakriti dosha using tongue images: pilot study. Indian Journal of Science and Technology. 2020.
• Suguna R, Veerabhadrappa. Identification and classification of Prakriti of human using facial features. IAES International Journal of Artificial Intelligence. 2024.
• Trivedi P, Patel V. Skin colour classification for Prakriti assessment using image processing and machine learning. 2025.
• Gupta S, et al. Towards standardization of Prakriti evaluation: a scoping review of modern assessment tools and their psychometric properties in Ayurvedic medicine. Journal of Ayurveda and Integrative Medicine. 2025.
• Venkatesh P, et al. Ayurvedic Prakriti Assessment Tools: a critical review of measurement properties, validation strategies, and clinical readiness. Frontiers in Medicine. 2025.

Disclaimer: AI Prakriti assessment tools are educational and supportive tools only. They are not a substitute for consultation with a qualified Ayurvedic practitioner or healthcare provider. Any decision about herbs, diet, Panchakarma, supplements, medication changes, or treatment protocols should be made with professional guidance, especially during pregnancy, chronic illness, active symptoms, or ongoing medication use.

References

1. Charaka Samhita — Deha prakriti
2. Easyayurveda (easyayurveda.com)
3. Frontiersin (frontiersin.org)
4. Researchgate (researchgate.net)
5. Journals (journals.plos.org)
6. Indjst (indjst.org)
7. Researchgate (researchgate.net)
8. Jisem-journal (jisem-journal.com)
9. Link (link.springer.com)
10. Nature (nature.com)
11. Pib (pib.gov.in)
12. Pib (pib.gov.in)
13. Reliability studies of diagnostic methods in Indian traditional Ayurveda medicine: An overview (2013), PubMed Central

The researchers used an Affymetrix genome-wide SNP array rather than whole-genome sequencing. They reported 52 SNPs that differed among the selected Prakriti groups at their stated statistical threshold after permutation testing. Of the 262 participants, 245 passed initial genotyping quality control, and smaller subsets were used after additional ancestry and outlier analyses. The investigators also examined PGM1, a gene involved in carbohydrate metabolism, as a possible correlate of features attributed to Pitta. They concluded that their preliminary findings supplied material for further study—not that a person’s complete Prakriti could be read directly from DNA.

This distinction matters. Prakriti is an Ayurvedic constitutional assessment based on a pattern of anatomical, physiological, psychological, and behavioural features. Genes may contribute to some of these features, but Prakriti is not equivalent to a single genotype, laboratory test, pulse finding, or consumer DNA report. “Ayurgenomics” is the research programme that investigates possible relationships between Ayurvedic phenotypes and modern genomic, epigenomic, transcriptomic, metabolic, and microbiome measurements. Its clinical applications remain investigational.

What Ayurgenomics Has Actually Found

Published studies have reported several associations, but they differ greatly in design, sample size, technology, and strength of evidence. Most examined selected groups of healthy people with strongly expressed constitutional features. They did not establish universal genetic profiles for every Vata, Pitta, or Kapha individual, and they did not validate genotype-based prescriptions for Ayurvedic medicines.

These findings are scientifically interesting because they suggest that carefully defined Ayurvedic phenotypes may sometimes correspond to measurable biological variation. However, association is not identity or destiny. Results obtained in extreme, preselected groups may not generalize to people with mixed Vata-Pitta, Pitta-Kapha, Vata-Kapha, or relatively balanced constitutions. Replication in larger, diverse, independently assessed populations is still necessary.

Herb Metabolism and the CYP450 Question

Cytochrome P450 enzymes participate in the metabolism of many medicines and other substances, and inherited variants in certain CYP genes can affect the handling of specific pharmaceutical drugs. The verified Prakriti study in this area examined selected CYP2C19 variants. It did not show that all Pitta individuals rapidly metabolize herbs or that all Kapha individuals require lower doses.

It is therefore incorrect to claim that CYP3A4 or CYP3A5 variants have been shown to make Pitta individuals require 30–50% more Ashwagandha or Turmeric. Likewise, the cited research does not demonstrate that CYP2C19 determines the safe dose of Pippali, or that CYP1A2 can be used to select doses of Tulsi, Neem, or Brahmi. A botanical preparation contains numerous constituents, and its absorption, transformation, transport, and elimination may involve several enzymes and non-CYP pathways. The plant part, extract method, formulation, food intake, other medicines, liver and kidney function, age, and product quality can all influence exposure.

Even when a pharmacogenetic result is clinically meaningful for a named prescription drug, it cannot be transferred automatically to an Ayurvedic herb that happens to interact with the same enzyme in a laboratory experiment. A clinically useful dosing rule requires validated information connecting a particular variant, a standardized preparation, measured exposure, safety, and patient outcomes. Such genotype-to-dose guidelines have not been established for Ashwagandha, Brahmi, Triphala, Turmeric, or Pippali.

Disease Vulnerability Is Not Yet Predictable from Prakriti Genomics

Ayurveda considers constitution when evaluating susceptibility, strength, prognosis, and treatment, but modern statements such as “Vata equals neurological disease,” “Pitta equals inflammatory disease,” or “Kapha equals diabetes” are oversimplifications when presented as fixed predictions. Classical assessment also considers the current disorder, affected tissues, digestive capacity, suitability, age, environment, season, strength, and numerous other factors.

No verifiable 2019 PLoS One study was found showing that Kapha-dominant people had higher polygenic risk scores for type 2 diabetes or metabolic syndrome while Vata-dominant people had higher scores for osteoporosis and anxiety. That claim should not be used to market Prakriti assessment as a genomic disease-screening test. Existing studies have identified exploratory associations with selected physiological measurements or disease cohorts, but they have not produced validated Prakriti-specific polygenic scores suitable for diagnosis, prevention, or treatment decisions.

Prakriti assessment may still contribute to a practitioner’s broader understanding of a patient, especially within traditional Ayurvedic clinical reasoning. It must not replace established screening for diabetes, cardiovascular disease, osteoporosis, cancer, psychiatric illness, or other conditions. Family history, symptoms, physical examination, validated risk calculators, and appropriate laboratory or imaging investigations remain essential.

The Microbiome Dimension

Prakriti-associated microbiome research is also preliminary. A 2018 study examined 16S rRNA profiles from 50 men and 63 women in a comparatively homogeneous rural population. Firmicutes and Bacteroidetes were the major phyla across all three groups. Overall alpha-diversity patterns were comparable, and beta-diversity analysis did not separate participants into clear Prakriti clusters. The investigators did identify certain less-abundant taxa that were enriched in particular groups, with notable differences between male and female results.

Smaller studies published in 2019 and 2021 likewise reported differences in the relative abundance of selected gut, oral, or skin organisms among Prakriti groups. These investigations are useful for generating hypotheses, but they do not prove that Kapha constitution inherently has low microbial diversity, a high Firmicutes-to-Bacteroidetes ratio, or a microbiome equivalent to metabolic syndrome.

There is consequently no validated rule for choosing probiotics, fermented foods, Triphala, or other interventions from Prakriti microbiome data. Microbiome composition is affected by diet, location, medications, sanitation, age, recent illness, sequencing methods, and many other variables. Commercial stool reports also vary in analytical quality and often lack proven clinical utility for prescribing treatment in otherwise healthy people.

Rasayana Selection: Classical Individualization, Not Genomic Matching

Classical Ayurveda already provides a detailed framework for individualization, but it is broader than genetic testing. Charaka Samhita, Vimana Sthana 8, describes a tenfold examination that considers the patient’s habitat and body, Prakriti and Vikriti, tissue excellence, compactness and build, measurements, suitability or habituation, mental strength, capacity for food and digestion, exercise capacity, and age. The text also warns that the strength and potency of treatment must be chosen after considering the patient and disease; otherwise medicine may cause harm.

This framework does not support selecting Ashwagandha from an FKBP5 result, Brahmi from the BDNF Val66Met variant, Triphala from a presumed Kapha microbiome signature, or Curcumin from inflammatory SNPs. Research on these plants and molecular pathways may offer hypotheses, but no clinical trials have validated those specific gene-herb matching rules. Fixed extract doses such as 600 or 900 mg of Ashwagandha, 300–450 mg of Brahmi, or 5 g of Triphala cannot be prescribed responsibly from genotype or Prakriti alone.

The Ayurvedic Pharmacopoeia of India serves a different purpose. Its monographs establish official standards concerned with the identity, purity, and strength of Ayurvedic drugs and ingredients. Pharmacopoeial quality is important, but the Pharmacopoeia does not certify genotype-specific indications or doses. A correctly identified, uncontaminated herb can still be unsuitable for a particular person, interact with medicines, or be used in an inappropriate preparation or amount.

What Responsible Precision Ayurveda Can Mean Today

A defensible form of precision Ayurveda begins with careful clinical assessment rather than a commercial gene report. It may integrate a qualified Ayurvedic evaluation with conventional diagnosis, medication review, laboratory findings, dietary history, allergies, organ function, pregnancy status, and monitoring of benefits and adverse effects. Genomics may be added when a healthcare professional identifies a medically established reason, such as a pharmacogenetic test linked to a particular prescription drug.

Ayurgenomics can also contribute at the research level by improving phenotype definition. Instead of grouping all patients with a biomedical diagnosis together, researchers may examine whether rigorously assessed constitutional patterns identify subgroups with different biomarkers or responses. For that approach to become clinically useful, assessment methods must be reproducible, studies must be prospectively registered and adequately powered, and results must be independently replicated before treatment recommendations are made.

Future work may eventually identify reliable relationships among Prakriti, genomics, epigenetics, metabolomics, microbiome patterns, drug response, and clinical outcomes. At present, however, the evidence supports continued investigation rather than routine genomic selection of rasayana herbs or constitution-based alteration of doses.

Using Consumer Genetic Data Safely

Direct-to-consumer DNA services commonly test a selected set of variants rather than providing a complete clinical analysis. A negative consumer result cannot rule out all medically important variants, and an apparently actionable result may need confirmation in a clinical laboratory. The National Human Genome Research Institute also notes that some consumer tests promote traits or interventions without a confirmed gene-to-phenotype relationship or demonstrated clinical utility.

Uploading raw DNA data to a third-party interpretation platform does not turn it into a validated Ayurvedic prescribing tool. Reports may differ because platforms use different databases, assumptions, and variant classifications. Privacy and data-sharing policies should also be reviewed before uploading genomic files. Most importantly, a list of CYP, BDNF, COMT, MTHFR, APOE, or HLA variants should not be used independently to start, stop, increase, or reduce an herbal or pharmaceutical treatment.

Actionable tip: Keep a complete list of medicines, Ayurvedic formulations, extracts, teas, and supplements you use, including brand, plant part, dose, and frequency. Share the list with both your Ayurvedic physician and conventional healthcare provider. When a genetic result appears medically important, request interpretation by a clinician or genetic counsellor familiar with the relevant condition or drug. Do not adjust Ashwagandha, Brahmi, Triphala, Turmeric, Pippali, or any prescription medicine solely from an online genotype report.

Ayurgenomics and genomic-guided Ayurveda remain emerging research fields. The associations described here are not established diagnostic tests or clinical dosing protocols. Consult a qualified Ayurvedic physician and an appropriately trained healthcare provider before using medicinal herbs, combining them with prescription drugs, or acting on pharmacogenetic or direct-to-consumer DNA results.

References

1. Nature (nature.com)
2. Link (link.springer.com)
3. Link (link.springer.com)
4. Classification of human population based on HLA gene polymorphism and the concept of Prakriti in Ayurveda (2005), PubMed
5. EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda (2010), PubMed
6. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed Central
7. Frontiersin (frontiersin.org)
8. Understanding the association between the human gut, oral and skin microbiome and the Ayurvedic concept of prakriti (2019), PubMed
9. Exploring the signature gut and oral microbiome in individuals of specific Ayurveda prakriti (2021), PubMed
10. Charaka Samhita — Rogabhishagjitiya Vimana
11. Ayurvedic Pharmacopoeia of India
12. Ayurvedic Pharmacopoeia of India
13. Ayurgenomics-based frameworks in precision and integrative medicine: Translational opportunities (2023), PubMed Central
14. Genome (genome.gov)

What Is Prakriti?

In classical Ayurveda, deha prakriti is the constitutional pattern formed during embryonic development through the relative predominance of the doshas. It is described as persisting through life, whereas vikriti denotes a present disturbance that may change with disease, diet, behavior, season, age, and other influences. Classical descriptions of prakriti formation consider the sperm and ovum, time of conception, condition of the uterus, maternal diet and regimen, and the interaction of the mahabhutas. These concepts belong to Ayurveda’s own theoretical framework and should not be presented as ancient descriptions of genes or molecular epigenetics.

In modern biology, epigenetics concerns regulation of gene activity without alteration of the underlying DNA sequence. Major mechanisms include DNA methylation, histone modification, and regulatory non-coding RNA. Some epigenetic states can persist through cell divisions, but this does not make every stable bodily characteristic an epigenetic trait or establish prakriti as a single molecular signature.

What the Human Studies Reported

Published studies have examined different biological layers and should not be merged into one set of findings. Their principal designs and observations are summarized below.

The 2015 genome-wide study began with 3,416 screened volunteers and selected 262 men aged 20 to 30 who met stringent criteria for a predominant prakriti. After quality control, 245 samples entered the genetic analyses. The investigators also compared the identified variant set with data from 297 people representing established Indian ancestry groups. One reported association involved a variant in PGM1 and the pitta group. The publication did not establish a clinically validated genetic test for prakriti.

The CYP2C19 study is sometimes described as evidence that pitta individuals express more cytochrome P450 enzymes or clear medicines faster. It measured inherited CYP2C19 genotypes rather than enzyme expression or drug concentrations. Its findings therefore cannot support a general rule about medicine metabolism in every person assigned to pitta prakriti.

The Prakriti–Microbiome Connection

A 2018 study analyzed gut microbiota in 135 healthy adults selected for extreme prakriti, and a 2021 study profiled gut and oral microbiomes from 272 healthy participants. The later study found a broadly shared core microbiome, with Prevotella, Bacteroides, and Dialister among the major gut genera, together with some group-associated microbial signatures. For example, Paraprevotella and members of Christensenellaceae were preferentially observed in the vata group. These observations do not establish fixed microbial profiles for every dosha or demonstrate that one prakriti necessarily has lower diversity, greater inflammation, or more efficient calorie extraction.

Epigenetics and Developmental Context

The 2015 methylation study provides the most direct human connection between prakriti research and an epigenetic mechanism. It identified group-associated DNA methylation patterns in whole blood and validated selected loci by bisulfite sequencing. The kapha-associated methylation finding near CDH22 was also associated with body-mass index within that dataset. Because methylation patterns can vary by tissue, age, and environmental exposure, a whole-blood association should not be interpreted as a permanent body-wide imprint.

The developmental origins of health and disease framework recognizes that conditions before conception, during pregnancy, and in early life can influence later health. Ayurveda likewise places constitutional formation within an embryological, parental, and maternal context. The comparison is conceptually useful, but the two systems employ different categories, methods, and standards of explanation.

Implications for Ayurvedic Care

Classical Ayurvedic clinical reasoning does not reduce treatment to constitution alone. Charaka’s examination framework considers prakriti together with present abnormality, patient strength, disease severity, place, season, digestive capacity, age, suitability, and the strength of the proposed treatment. Two people assigned the same prakriti may therefore receive different dietary, behavioral, or medicinal recommendations. Genomic and methylation associations do not establish prakriti-specific rasayana prescriptions, herb combinations, or dosage schedules.

Prakriti Assessment in Research and Practice

The 2015 genome-wide project used a staged process rather than a brief self-test. Senior Ayurvedic physicians assessed participants, a software-assisted assessment was performed independently, and another physician team reviewed concordance. Only participants with at least 60 percent predominance of one prakriti and agreement across all three stages were selected. This process improved separation of the research groups but excluded many mixed constitutions encountered in routine practice.

Modern prakriti instruments vary greatly in their questions, scoring systems, training requirements, and validation. A 2025 critical review identified 64 unique assessment tools developed between 1987 and 2024. Only 20 had undergone any reported validity or reliability testing, and none fulfilled every criterion in the review’s evaluation framework. A responsible assessment therefore combines lifelong constitutional characteristics with examination by a qualified practitioner and keeps prakriti distinct from current symptoms or imbalance.

A Practical Starting Point

For personal observation, note characteristics that have remained relatively consistent across healthy periods, such as natural frame, baseline skin qualities, appetite pattern, temperature preference, sleep tendency, and usual pace of activity. Do not use a self-assigned dosha label to diagnose disease, interpret genetic risk, predict medicine response, or begin an herbal regimen.

Limitations and Cautions

Prakriti genomics remains an association-based field. The principal genome-wide variant and methylation studies selected healthy men aged 20 to 30 with strongly predominant constitutions, so their findings cannot automatically be generalized to women, children, older adults, mixed prakriti, or people with illness.

• Different studies measured different layers—DNA variants, methylation, RNA expression, biochemical values, or microorganisms—and these results are not interchangeable.
• Cross-sectional associations do not establish that a variant, methylation mark, or microorganism causes a prakriti.
• Diet, geography, ancestry, medication use, lifestyle, and laboratory methods can influence molecular and microbiome measurements.
• Prakriti classification methods are not standardized across all research and clinical settings.
• The cited human studies did not test a pathway that converts a prakriti result into genomic diagnosis, individualized drug dosing, or a universal herbal protocol.

Safety and Disclaimer

Prakriti-genomics findings should not replace medical diagnosis, validated pharmacogenomic testing, genetic counseling, or prescribed treatment. This article does not provide individualized herb or dosage instructions. Some Ayurvedic preparations may contain lead, mercury, or arsenic in potentially toxic amounts. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using medicinal products, especially during pregnancy or breastfeeding, for a child, when taking prescription medicines, or when managing an existing health condition.

References

1. Charaka Samhita — Deha prakriti
2. Charaka Samhita — Rogabhishagjitiya Vimana
3. NCBI
4. Translational-medicine (translational-medicine.biomedcentral.com)
5. Onlinelibrary (onlinelibrary.wiley.com)
6. Translational-medicine (translational-medicine.biomedcentral.com)
7. Nature (nature.com)
8. Frontiersin (frontiersin.org)
9. Researcher (researcher.manipal.edu)
10. Exploring the signature gut and oral microbiome in individuals of specific Ayurveda prakriti (2021)
11. Niehs (niehs.nih.gov)
12. Frontiersin (frontiersin.org)
13. NCCIH
14. Ayurvedic Pharmacopoeia of India

That question is scientifically legitimate, but the clinical claims often made from it are much stronger than the evidence. The studies reviewed here do not show that a Pitta-predominant patient needs a higher antihypertensive dose, that a Kapha-predominant patient clears medicines slowly, or that Vata, Pitta, and Kapha can substitute for a pharmacogenetic test. The available literature consists mainly of cross-sectional studies of healthy volunteers, molecular association studies, and reviews.

Peer-reviewed work has appeared in the Journal of Translational Medicine, Proceedings of the National Academy of Sciences, Scientific Reports, Evidence-Based Complementary and Alternative Medicine, and the Journal of Ayurveda and Integrative Medicine. An ACS Chemical Biology article discussed Ayurgenomics as a framework for stratified medicine, but it was not a clinical dosing trial.

Disclosure: Ayurgenomics remains an exploratory research field. Do not change the dose, timing, or choice of any prescribed medicine on the basis of Prakriti. Medication decisions should be made with a qualified physician; Ayurvedic treatment should be supervised by a properly qualified Ayurvedic practitioner, especially when herbs and prescription medicines are combined.

The Ayurgenomics Framework: What Researchers Are Actually Studying

In classical Ayurveda, Prakriti is the relatively stable constitution established from the beginning of life, while a person’s current doshic disturbance is assessed separately. Charaka Samhita, Vimana Sthana 8/95 describes factors associated with the formation of constitution, and 8/96–99 describes characteristics of Kapha-, Pitta-, and Vata-predominant constitutions. Modern Ayurgenomics does not directly prove doshas as molecular entities; it tests whether people classified by an Ayurvedic phenotype show reproducible differences in measurable biological variables.

The most defensible hypothesis is therefore limited: a carefully assessed phenotype may enrich a study group for certain genetic, transcriptomic, biochemical, epigenetic, or metabolic features. Demonstrating such enrichment would not by itself prove that Prakriti predicts response to a medicine. That requires prospective pharmacokinetic or clinical-outcome studies in which drug exposure, therapeutic response, and adverse events are measured directly.

A foundational 2008 study led by Bhavana Prasher and Mitali Mukerji screened 850 volunteers and ultimately included 96 unrelated, ethnically matched healthy participants with predominant Vata, Pitta, or Kapha phenotypes. Contrary to a frequently repeated description, the final sample was not 262 men: it included 48 men and 48 women. The investigators reported group differences in selected biochemical and hematological measures and in gene-expression categories related to processes such as transport, immune response, cyclin-dependent kinase regulation, and blood coagulation. The work was exploratory, used extreme constitutional types, and did not test any drug.

Genome-Wide Variation: What the 2015 Study Found

The 2015 Scientific Reports study is also often misquoted. Researchers assessed 3,416 healthy men aged 20–30, but genome-wide SNP analysis was performed on 262 men with strongly predominant and concordantly classified Prakriti: 94 Vata, 75 Pitta, and 93 Kapha. After permutation testing, 52 SNPs differed among the groups at the study’s stated significance threshold, and principal-component analysis separated the selected study participants.

The authors also applied a statistical model to 297 Indian population samples of known ancestry. Only 37 of those samples satisfied the model’s criteria and were projected into the proposed Prakriti clusters. This was a limited secondary analysis, not independent clinical validation of a Prakriti diagnostic test. The paper further reported Pitta-associated markers in and around PGM1, a gene involved in carbohydrate metabolism.

Importantly, the study did not report that Pitta was enriched for CYP3A4 or CYP2C9 variants, that Kapha was defined by slow drug clearance, or that Vata carried catecholamine-pathway variants that predict psychoactive-drug sensitivity. Those specific statements are not supported by the paper and should not be used in patient counseling.

CYP2C19 and Prakriti: The Main Direct Pharmacogenomic Association

The clearest published Prakriti–drug-metabolism association comes from a study of CYP2C19, published online in 2009 and in its final journal volume in 2011. Investigators screened 489 healthy volunteers and recruited 132 unrelated participants with predominant Prakriti: 63 Kapha, 43 Pitta, and 26 Vata. The sample included both men and women.

Using the alleles tested in that study, the authors classified 91% of the Pitta group as “extensive metabolizers,” while the genotype category labeled “poor metabolizer” occurred in 31% of Kapha, 12% of Vata, and 9% of Pitta participants. The CYP2C19*2/*3 genotype was reported only in Kapha and was associated with Kapha in the study, with a reported odds ratio of 3.5 and a p value of .008.

This result is noteworthy, but its boundaries matter. The researchers studied genotype distribution; they did not administer a CYP2C19 substrate, measure plasma drug concentrations, compare therapeutic outcomes, or establish safe doses for any Prakriti. Allele coverage and metabolizer terminology have also evolved since the study. It is therefore evidence for a possible association requiring replication, not evidence that all Kapha individuals are slow metabolizers or that Prakriti can replace clinical CYP2C19 genotyping.

A Corrected Evidence Map

The strongest verified studies support molecular correlation, not Prakriti-based prescribing. The following table separates what each study observed from the clinical conclusions it cannot establish.

None of these studies was a randomized medication trial, and none produced a clinically validated dosing algorithm. A molecular difference can be real yet still be too small, too population-specific, or too poorly replicated to guide treatment for an individual.

What the Research Demonstrates—and What It Does Not

The evidence supports a modest conclusion: strongly selected Prakriti groups have shown differences in some molecular and biochemical measurements. It does not yet show that a patient’s Prakriti reliably predicts the concentration, benefit, or toxicity of a prescribed drug. Several methodological issues explain why the gap remains large.

Study Populations and Replication

Samples have generally been small after strict phenotypic selection, and some influential studies included only young Indian men or focused on particular Indian ancestry groups. The 2008 study included women, but sex-specific expression differences and greater within-group variability were also observed. Robust clinical use would require independent replication across sexes, ages, regions, ancestries, disease states, and treatment settings.

Assessment Reliability

Prakriti classification is not yet measured by one universally accepted research instrument. A 2025 critical review identified 64 distinct assessment tools used from 1987 through 2024; only 20 had undergone any validation or reliability testing, and only two met seven of the nine criteria used by the reviewers. When studies use different questionnaires, scoring rules, software, or physician judgments, apparently similar labels may not define equivalent groups.

Prakriti, Vikriti, and Confounding

Classical Prakriti should not be described as something that changes with each season, diet, or current illness. Those factors may alter present symptoms, doshic imbalance, laboratory values, gene expression, or how constitution is perceived during assessment. Research must therefore distinguish stable constitutional classification from current vikriti and control for ancestry, body composition, diet, sleep, medications, geography, socioeconomic conditions, and other environmental influences.

Association Is Not Prediction

A statistically different allele frequency between groups does not mean that every person in a group carries the allele, and it does not show that the allele changes a clinical outcome. A useful predictor must add reproducible information beyond established factors, be tested in an external population, and improve a decision such as drug choice, starting dose, monitoring, or avoidance. Existing Ayurgenomics studies have not yet crossed that threshold.

Metabolomics and Other Molecular Correlates

A study published online in 2017 and in print in 2018 in the Journal of Ayurveda and Integrative Medicine examined fasting plasma from 38 healthy men and reported differences in inferred metabolic pathways among Prakriti groups, including branched-chain amino-acid and glycerolipid processes in Pitta and catecholamine, arachidonic-acid, and hydrogen-peroxide processes in Vata.

That small untargeted metabolomics study did not establish that Kapha patients respond differently to NSAIDs or corticosteroids, that Pitta patients clear protein-bound medicines faster, or that any group has a predictable inflammatory baseline. Such clinical inferences would require targeted assays, replication, drug-exposure measurements, and patient outcomes.

A separate PNAS study linked EGLN1 variation, constitution-based stratification, and high-altitude adaptation. This supports the broader idea that detailed phenotyping can help reveal biological associations. It does not validate a universal relationship between dosha and drug metabolism.

Established Pharmacogenomics Must Remain Separate

Conventional pharmacogenomics already contains well-studied gene–drug pairs, but these should not be retrofitted onto Prakriti without direct evidence. Clinical Pharmacogenetics Implementation Consortium guidelines explain how available genotype results may be used for particular medicines; they do not endorse Vata, Pitta, or Kapha as surrogate genotypes.

Warfarin

Warfarin dose requirements can be influenced by variants in CYP2C9, VKORC1, and CYP4F2, together with clinical factors. Current CPIC guidance addresses those measured genotypes. No verified study reviewed here shows that Kapha is enriched for reduced-function CYP2C9 variants or that Prakriti predicts bleeding on warfarin. Anticoagulant dosing must never be altered from constitutional appearance.

Codeine

CYP2D6 genotype can affect conversion of codeine to morphine, and CPIC provides recommendations for known CYP2D6 phenotypes. The Ayurgenomics studies reviewed here do not establish a distribution of CYP2D6 phenotypes by Prakriti. A proposed Vata sensitivity to codeine or psychoactive medicines is therefore unverified.

Statins

The current CPIC statin guideline focuses on SLCO1B1, ABCG2, and CYP2C9 in relation to statin exposure and musculoskeletal symptoms. It does not describe Pitta as a rapid CYP3A4 phenotype or Kapha as a slow-clearance phenotype. Body build or a dosha label cannot be used to estimate statin myopathy risk.

Clinical Implications: What Practitioners Can and Cannot Do Today

Clinicians should not use Prakriti to determine prescription-drug doses. It may remain part of a traditional Ayurvedic assessment, but it is not a validated substitute for medication history, renal and hepatic assessment, therapeutic drug monitoring, evidence-based pharmacogenetic testing, or disease-specific prescribing guidance.

1. Do not infer metabolizer status from dosha. A Pitta label does not prove rapid clearance, and a Kapha label does not prove poor metabolism or accumulation.
2. Use validated gene–drug guidance when relevant. Where a recognized guideline exists, decisions should be based on the actual genotype or phenotype and the patient’s clinical circumstances.
3. Review herb–drug combinations individually. Interaction risk depends on the herb, preparation, dose, product quality, medicine, and patient—not on an unvalidated constitutional shortcut.
4. Keep Ayurvedic reasoning within its evidence and scope. A qualified practitioner may consider Prakriti alongside agni, current doshic imbalance, strength, age, season, diet, and disease, but this does not authorize changing a pharmaceutical dose.

Anyone taking anticoagulants, antiplatelet medicines, immunosuppressants, anticonvulsants, psychiatric medicines, chemotherapy, or other narrow-therapeutic-index drugs should seek medical advice before adding herbal products. New fatigue, bleeding, jaundice, rash, fainting, severe gastrointestinal symptoms, or other suspected adverse effects require prompt clinical evaluation rather than dosha-based self-correction.

The Road Ahead: What Research Is Needed

Ayurgenomics could become more informative if future studies move from retrospective molecular association to prospective clinical testing. The essential question is not merely whether groups differ, but whether Prakriti adds accurate, reproducible, and clinically useful prediction after known genetic and clinical variables are included.

• Pre-registered, adequately powered studies using clearly specified and independently validated Prakriti instruments
• Direct pharmacokinetic testing with defined probe drugs, measured concentrations, and prespecified outcomes
• Replication in women and men across ages, ancestries, regions, body compositions, and disease populations
• Parallel measurement of relevant genotypes, liver and kidney function, diet, co-medication, adherence, and environmental factors
• Separation of innate Prakriti from current vikriti and temporary disease-related phenotypes
• External validation showing that Prakriti improves prediction beyond ordinary clinical assessment and established pharmacogenomics
• Prospective evaluation of adverse drug reactions, therapeutic response, and cost-effectiveness before clinical implementation

Until those requirements are met, Ayurgenomics is best understood as a promising phenotype-to-biology research program, not a bedside dosing system. Its value may lie in generating hypotheses and refining cohorts for investigation, but clinical utility must be demonstrated rather than assumed.

A Note on Traditional Ayurveda

Classical Ayurveda does emphasize individualized examination. In Charaka Samhita, Prakriti is one relevant feature of the patient, not the sole basis of treatment. The physician is expected to assess the person, the disorder, strength, current imbalance, suitability, diet, environment, and the properties of the proposed intervention. The Prakriti passages are in Vimana Sthana 8/95–99, not Sharira Sthana Chapter 4.

This individualized orientation is conceptually compatible with the goal of precision medicine, but conceptual similarity is not scientific equivalence. Pharmacogenomics links particular variants to particular drugs under defined conditions; Prakriti is a multidimensional clinical construct. Respecting both traditions requires keeping those categories distinct until direct evidence justifies a bridge.

Educational content cannot replace personal medical care. Consult a qualified physician before changing any medicine and a qualified Ayurvedic practitioner for individualized Ayurvedic assessment. Seek urgent care for serious or rapidly worsening symptoms.

References

1. Link (link.springer.com)
2. Charaka Samhita — Prakriti
3. Charaka Samhita — Rogabhishagjitiya Vimana
4. Nature (nature.com)
5. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
6. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed Central
7. Pubs (pubs.acs.org)
8. Pnas (pnas.org)
9. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed
10. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed Central
11. Frontiersin (frontiersin.org)
12. Cpicpgx (cpicpgx.org)
13. Cpicpgx (cpicpgx.org)
14. Cpicpgx (cpicpgx.org)

Metabolomics can add an objective biochemical layer to research on complex Ayurvedic care, but it does not by itself prove that a treatment works, identify which ingredient caused a change, or confirm an Ayurvedic diagnosis. The most relevant recent example is a 2024 study in the Journal of Ayurveda and Integrative Medicine, not the Journal of Ethnopharmacology. It followed people with rheumatoid arthritis (RA) who received a three-month Ayurveda whole-system intervention. The study reported clinical improvement together with movement of selected serum metabolites toward levels observed in healthy controls. These findings are scientifically interesting, but the uncontrolled design makes them preliminary rather than definitive validation.

What Metabolomics Actually Measures

Metabolomics is the large-scale study of small molecules, or metabolites, in cells, tissues, organisms, and biological fluids such as blood and urine. They include amino acids, sugars, organic acids, fatty acids, lipids, and products of normal metabolism, diet, medicines, gut microbes, and environmental exposure. Because concentrations can change rapidly, a metabolomic profile is a biochemical snapshot obtained under specified conditions, not a permanent molecular identity.

Two common platforms are nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry, often coupled to chromatography. NMR can quantify abundant metabolites reproducibly with limited sample preparation, while mass spectrometry usually detects a broader range at greater sensitivity. Neither method measures every blood metabolite, and the number identified depends on the instrument, preparation, reference libraries, and analysis. Claims that a standard panel always quantifies a fixed 500 or 1,000 metabolites are misleading.

Metabolomics can show whether groups differ, whether a profile changes during treatment, and whether changes correlate with clinical outcomes. It cannot eliminate placebo-related influences on sleep, food, stress, or activity, all of which may affect metabolism. A changed metabolite also does not prove a specific mechanism without targeted confirmation and suitable controls.

What the 2024 Rheumatoid Arthritis Study Actually Did

Rastogi and colleagues enrolled 37 patients who met criteria for RA and were also assessed as having Amavata within the study’s Ayurvedic framework. Participants received a three-month intervention comprising oral medicines, local therapy, and dietary recommendations. Serum was assessed at baseline, six weeks, and three months; 57 healthy participants supplied comparison samples. The researchers used an 800 MHz NMR spectrometer, not LC-MS.

Sample numbers were 37 at baseline, 26 at six weeks, and 36 at three months. The paper reported reductions in DAS28-ESR, an Ama assessment score used by the investigators, swollen-joint count, and tender-joint count. Because every treated participant received a package of care, the study observed the combined intervention rather than isolating one herb, formulation, or dietary instruction.

Compared with healthy controls, the baseline RA group had higher circulating succinate, lysine, mannose, creatine, and 3-hydroxybutyrate, and lower alanine. After treatment, these abnormalities and several derived ratios moved toward the healthy-control pattern. The authors interpreted this convergence as evidence that NMR metabolomics can monitor biochemical change alongside clinical change.

• Clinical change: DAS28-ESR, swollen-joint count, tender-joint count, and the investigators’ Ama score decreased.
• Metabolic change: Selected amino-acid, carbohydrate, ketone-body, and energy-related metabolites shifted toward the comparison profile.
• Not demonstrated: The paper did not report suppression of COX-2 or LOX, normalization of kynurenine metabolism, altered ceramides, or reduced oxidized lipids.
• Not compared: It did not test Guggulu, Ashwagandha, diet, or local therapy against placebo or against one another.

Why the Findings Are Promising but Not Causal Proof

The study was not a randomized controlled trial with a matched treatment-control group. Healthy volunteers defined a comparison metabolic pattern, but they did not control for time, regression to the mean, diet, concurrent care, expectations, or natural fluctuation in RA activity. The pre-post shift therefore shows association with the treatment period, not proof that the intervention alone caused it.

The findings also do not show reversal of RA or equivalence to a disease-modifying antirheumatic drug. Serum succinate and other metabolites are biologically relevant, but their concentrations are influenced by many tissues and behaviors. The defensible conclusion is narrower: parallel clinical and NMR-detectable metabolic changes occurred in a small cohort receiving whole-system Ayurvedic care.

The “Black Box” Clinical Design

A separate 2025 paper in JMIR Research Protocols described a single-arm, community-based “black box” study of a composite Ayurveda regimen for RA. It was a protocol and progress report, not a completed efficacy paper. The study enrolled 240 participants at six centers; 222 completed the final follow-up while analysis was still under way.

Participants received Ayush-SG and Rasnasaptak Kashaya for 84 days, with additional customized treatment according to presentation and associated complaints. Planned outcomes included DAS28-ESR, biochemical and inflammatory markers, disability, pain, analgesic or NSAID use, and adverse events. Metabolomics was not an outcome. “Black box” referred to evaluating a composite, partly individualized regimen as a package rather than dissecting every ingredient. This resembles practice, but without randomization and a concurrent comparator it cannot estimate how much change exceeds usual care, expectancy, or natural variation.

Prakriti and Metabolic Signatures

The frequently cited Prakriti metabolomics study was published in 2018, with online publication in 2017—not in 2024. It examined fasting plasma from 38 healthy men classified into dominant Vata, Pitta, or Kapha groups. Using liquid chromatography–quadrupole time-of-flight mass spectrometry, the researchers selected 76 metabolites after statistical filtering and reported different pathway patterns among the groups.

Reported patterns included catecholamine, arachidonic-acid, and hydrogen-peroxide-related processes in Vata; branched-chain amino-acid catabolism, androgen biosynthesis, and glycerolipid-related processes in Pitta; and aromatic amino-acid, sphingolipid, and pyrimidine-related processes in Kapha. These exploratory associations from a small, male-only sample do not establish a fixed signature for every person, validate pulse diagnosis, or predict treatment response.

A related 2015 Scientific Reports study performed genome-wide SNP analysis in 262 well-classified men selected after screening 3,416 people. It reported 52 SNPs that differed among the dominant Prakriti groups under its statistical criteria. This was a genomic-variation study, not a gene-expression study. Replication, broader demographic inclusion, prespecified classifiers, and external validation remain necessary.

Bridging the Single-Component and Whole-System Divide

Defined-product trials ask whether a specified intervention produces benefit relative to a comparator, then investigate mechanism, dose, pharmacokinetics, and safety. Whole-system Ayurveda research asks whether a package of medicines, diet, procedures, and behavioral advice improves outcomes. Metabolomics can describe the biological response to that package, but it does not replace controlled clinical outcomes or product-quality testing.

Chemically profiling an Ashwagandha, Haridra, or Guggulu preparation is phytochemical characterization. Detecting plant-derived metabolites after dosing is exposure or pharmacokinetic evidence. Showing that endogenous metabolic networks change during treatment is clinical metabolomics. None alone proves efficacy; together, in controlled research, they can clarify identity, exposure, response, and outcome.

Parallels with Precision Medicine

Precision medicine combines clinical characteristics with genomic, environmental, behavioral, and biomarker data to study variation between individuals. The NIH All of Us Research Program is building a diverse dataset containing surveys, electronic health records, physical measurements, wearables, biospecimens, and genomic data, with a goal of data from at least one million participants. An NIH-supported exposomics project is applying untargeted metabolomics to samples from 5,600 participants.

This creates a conceptual parallel with Ayurveda’s emphasis on individualized assessment, but the frameworks are not interchangeable. Prakriti is a traditional constitutional construct assessed through clinical features; precision medicine uses measurements and prediction models for defined outcomes. Research can test whether Prakriti adds reproducible predictive information beyond age, sex, ancestry, diet, disease severity, and biomarkers. It should not assume equivalence before testing.

Where Herb-Specific Metabolomics Evidence Stands

Human metabolomic evidence for individual Ayurvedic herbs is much thinner than the original claims suggested. Chemical profiling of Ashwagandha, Guggulu, Guduchi, Shatavari, or Haridra extracts is not automatically evidence of systemic effects in patients, and animal or cell metabolomics is not proof of a human clinical effect. A defensible evidence chain separates formulation chemistry, exposure, biomarker response, symptom change, and safety.

1. Identity and quality: Verify botanical material, plant part, manufacture, contaminants, and marker compounds using pharmacopoeial or validated standards.
2. Exposure: Determine which constituents or metabolites reach blood after the actual oral preparation.
3. Biological response: Measure prespecified pathways while controlling diet, collection time, medicines, and other confounders.
4. Clinical relevance and safety: Compare validated outcomes, adverse events, laboratory abnormalities, interactions, and contamination with an appropriate control.

The Main Limitations of Current Research

Small samples are a recurrent problem. The RA cohort began with 37 patients, while the Prakriti study included 38 healthy men. With hundreds or thousands of features, small studies are vulnerable to chance findings, model overfitting, and optimistic classification accuracy. False-discovery-rate correction helps, but independent replication remains essential.

Fasting status, meal composition, exercise, smoking, alcohol, time of day, menstrual status, sample-processing delay, storage, medicines, supplements, gut microbiota, and recent illness can alter metabolites. Standard operating procedures, pooled quality controls, transparent processing, and data deposition improve reproducibility.

Metabolite identification may be tentative in untargeted studies and require confirmation with an authentic standard. The Human Metabolome Database and the NIH-supported Metabolomics Workbench aid annotation and data sharing, but database matching does not substitute for experimental confirmation.

What Better Studies Should Do Next

Future Ayurveda metabolomics research should preregister outcomes, use adequately powered comparator groups, document every intervention component, verify product identity and contaminants, standardize diet and sampling time where feasible, and confirm important metabolites with targeted assays. Trials should report conventional outcomes, adverse events, medication changes, and longer follow-up rather than treating a molecular signature as a surrogate for patient benefit.

For individualized care, researchers can test whether clinical features, Prakriti assessment, and baseline metabolites predict response. Models need separate training and validation cohorts; performance in the dataset used to build a classifier is not enough for clinical use. Multi-omics may deepen interpretation, but more data layers cannot repair weak design.

The careful conclusion is that metabolomics is a valuable measurement tool for Ayurveda research. The 2024 RA study showed that whole-system care can be studied alongside serum metabolic change, and Prakriti studies provide exploratory group-level associations. Neither validates Ayurveda as a whole, proves specific herb mechanisms, nor justifies replacing established RA treatment.

Safety note: Rheumatoid arthritis can cause irreversible joint damage and usually requires medical assessment and disease-modifying treatment. Do not stop prescribed medicines or add Ayurvedic products on the basis of metabolomic findings. Some Ayurvedic preparations may contain toxic metals, and herbal products can interact with medicines. Consult a qualified Ayurvedic practitioner and the clinician managing your RA, and use products with reliable identity, quality, and contaminant testing.

References

1. Ebi (ebi.ac.uk)
2. Ebi (ebi.ac.uk)
3. Ebi (ebi.ac.uk)
4. Clinical metabolomics investigation of rheumatoid arthritis patients receiving ayurvedic whole system intervention (2024), PubMed
5. Clinical metabolomics investigation of rheumatoid arthritis patients receiving ayurvedic whole system intervention (2024), PubMed Central
6. Researchprotocols (researchprotocols.org)
7. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed
8. Plasma metabolomics reveal the correlation of metabolic pathways and Prakritis of humans (2018), PubMed Central
9. Nature (nature.com)
10. Allofus (allofus.nih.gov)
11. Allofus (allofus.nih.gov)
12. Hmdb (hmdb.ca)
13. Commonfund (commonfund.nih.gov)
14. Niams (niams.nih.gov)
15. NCCIH
16. FDA

Ayurveda individualizes treatment, but Prakriti alone does not reliably predict how a particular person will metabolize or respond to a conventional medicine. Molecular studies have identified preliminary associations between selected constitutional groups and gene expression, genetic variants, DNA methylation, and CYP2C19 genotypes; these findings remain exploratory and cannot replace validated pharmacogenetic testing, clinical examination, or therapeutic monitoring.

The interdisciplinary field commonly called Ayurgenomics examines whether carefully assessed Ayurvedic phenotypes correspond to measurable biological patterns. Its most useful contribution may be the development of testable questions about human variability. Its present findings do not justify assigning a drug, changing a prescription dose, or predicting an adverse reaction from dosha constitution alone.

Understanding Prakriti as an Ayurvedic Constitution

Prakriti is the individual constitution described in Ayurveda as being established through factors operating around conception. Classical descriptions recognize seven major deha-prakriti groupings: Vata, Pitta, Kapha, the three dual-dosha combinations, and sama-doshaja, in which the doshas are comparatively balanced. Prakriti is treated as a constitutional baseline rather than a diagnosis of disease.

Traditional assessment is multidimensional. It considers recurring characteristics such as body build, movement, appetite, digestion, temperature tolerance, skin and hair qualities, sleep, endurance, speech, emotional tendencies, and habitual patterns. A constitution should therefore be assessed through a structured clinical interview and observation rather than a brief personality quiz or a single physical feature.

Prakriti and Vikriti Are Not Interchangeable

Vikriti denotes the person’s present departure from balance. Symptoms, dosha aggravation, digestive disturbance, tissue involvement, season, diet, medicines, age, environment, and the stage and strength of disease may alter the current presentation without changing the underlying constitutional classification. Ayurvedic management is consequently based on the present clinical state as well as Prakriti.

Prakriti Is One Part of a Larger Examination

Charaka Samhita’s tenfold examination in Vimanasthana includes Prakriti and Vikriti together with tissue quality, bodily compactness, measurements, suitability or adaptation, mental strength, digestive and assimilative capacity, exercise capacity, and age. This framework prevents constitutional typing from becoming the sole basis of treatment and helps the physician judge the patient’s strength and the appropriate intensity of therapy.

What Ayurgenomics Studies Have Reported

Ayurgenomics studies have generally selected people who display relatively clear Vata-, Pitta-, or Kapha-predominant characteristics. Researchers have then compared molecular measurements between those groups. This design can identify group-level associations, but it does not establish that a constitutional label determines a person’s genotype, drug concentration, clinical response, or risk of toxicity.

The 2005 HLA-DRB1 Study

A study of 76 healthy participants compared 14 HLA-DRB1 alleles across constitution groups. In that sample, HLA-DRB1*02 was absent from the Vata group, HLA-DRB1*13 was absent from the Kapha group, and HLA-DRB1*10 occurred more frequently in Kapha than in the other predominant groups. The small sample and multiple allele comparisons make these findings hypothesis-generating rather than clinically diagnostic.

HLA-DRB1 associations must not be confused with pharmacogenetic testing for other HLA loci. The study did not establish that Pitta constitution predicts drug hypersensitivity, nor did it examine the clinically actionable HLA-B variants used with allopurinol or carbamazepine.

The 2008 Gene-Expression Study

A 2008 Journal of Translational Medicine study, indexed as PMID 18782426, evaluated 96 unrelated healthy adults classified as 39 Vata, 29 Pitta, and 28 Kapha. The investigators reported differences in biochemical measurements and pooled peripheral-blood gene-expression profiles. Functional categories included transport, immune response, coagulation, and regulation of cellular processes.

The microarray analysis identified 159 differentially expressed genes in the male comparison and 92 in the female comparison, with only five genes shared between the two lists. Eighteen genes were subsequently assessed by quantitative PCR and eight followed the corresponding microarray pattern. These results indicate possible biological heterogeneity among highly selected constitution groups, but they do not constitute a pharmacogenomic dosing rule.

The 2011 CYP2C19 Association

A study of 132 unrelated healthy participants examined CYP2C19 genotypes in relation to Prakriti. Extensive-metabolizer genotypes were more prominent in the Pitta group, whereas poor-metabolizer genotypes, particularly CYP2C19*2/*2, were more frequent in the Kapha group. The Vata group was not the group most strongly associated with poor-metabolizer alleles.

This was a genotype-frequency association in a limited cohort. It did not demonstrate that all Kapha-predominant people are poor metabolizers or that a Pitta-predominant person will metabolize every CYP2C19 substrate rapidly. CYP2C19 phenotype depends on the person’s actual diplotype and may also be modified by interacting medicines, illness, adherence, and other clinical factors.

The 2015 DNA-Methylation Analysis

A separate investigation selected 147 healthy young men after screening a much larger population and compared DNA-methylation patterns among predominant Prakriti groups. The analysis reported group-associated methylation signals involving LHX1 in Vata, SOX11 in Pitta, and CDH22 in Kapha. Methylation near CDH22 in the Kapha group was also examined in relation to body-mass index.

DNA methylation is influenced by cell composition, age, exposures, nutrition, and other environmental conditions. A cross-sectional methylation signature therefore cannot be interpreted as a permanent constitutional gene or as proof that a particular dosha causes a metabolic disease.

The 2015 Genome-Wide SNP Analysis

A genome-wide study published in Scientific Reports assessed 262 well-classified healthy men selected after screening 3,416 volunteers. It identified 52 single-nucleotide polymorphisms whose frequencies differed among the three predominant groups at the study’s specified significance threshold. The analysis highlighted an association involving PGM1 and the Pitta phenotype and compared the selected groups with ancestry information from Indian population datasets.

The reported units were 52 genetic variants, not 52 genes. The analysis supported the possibility that constitution groups captured some reproducible phenotypic structure in that cohort, but it did not validate a commercial genetic test for Prakriti or establish a drug-response algorithm.

Verified Evidence Map

The principal human studies differ substantially in design, sample selection, biological measurement, and clinical relevance. Reading them together requires separating molecular association from demonstrated treatment utility.

Where Pharmacogenomics Is Clinically Actionable

Clinical pharmacogenomics uses a patient’s directly measured genotype together with drug-specific guidelines. The result applies to a defined gene-drug pair, not to every medicine and not to an entire constitutional category. Actionable recommendations are developed from pharmacokinetic, clinical-outcome, and adverse-reaction data and are periodically updated as new evidence is evaluated.

CYP2C19, Clopidogrel, and Proton-Pump Inhibitors

CYP2C19 genotype can affect formation of clopidogrel’s active metabolite and the probability of achieving adequate antiplatelet activity. Clinical Pharmacogenetics Implementation Consortium guidance provides genotype-based recommendations for appropriate cardiovascular and neurovascular indications. Several proton-pump inhibitors are also substantially metabolized through CYP2C19, and CPIC guidance addresses how metabolizer status may affect exposure, efficacy, and adverse effects.

A dosha assessment cannot identify a CYP2C19 diplotype. When CYP2C19 status could materially alter treatment, the appropriate tools are a validated laboratory test, the medicine’s indication, the patient’s medical history, interacting drugs, and a recognized pharmacogenomic guideline.

HLA-B and Severe Cutaneous Reactions

HLA-B*58:01 is associated with a markedly increased risk of severe cutaneous adverse reactions from allopurinol, and genotype-informed guidance recommends avoiding allopurinol in a person who tests positive. For carbamazepine, recommendations consider HLA-B*15:02 and HLA-A*31:01 because of their associations with serious cutaneous reactions in relevant populations.

These are specific allele-drug relationships. The earlier HLA-DRB1 constitution study did not test these alleles and cannot be used as a preliminary replacement for HLA-B or HLA-A genotyping. Pitta constitution, skin sensitivity, heat intolerance, or a history of inflammatory symptoms does not establish the presence or absence of an actionable HLA allele.

Why Prakriti Cannot Substitute for Genotyping

People within the same Prakriti category remain genetically diverse, while the same pharmacogenetic allele can occur in more than one constitutional group. An association detected between two groups changes only the estimated frequency of a marker within the studied sample. It does not reveal which individual carries that marker, and it may change when ancestry, sex, age, recruitment criteria, or classification methods differ.

The 2017 phenytoin study illustrates this distinction. Among 351 patients receiving phenytoin monotherapy, Prakriti was not associated with CYP2C9 or CYP2C19 genotype, measured phenytoin concentration, or metabolic phenotype. CYP2C9*1/*3, however, was associated with toxic concentrations. Direct pharmacogenetic information was therefore more relevant than constitution for this specific drug.

Drug response also depends on renal and hepatic function, body composition, age, pregnancy, diet, adherence, smoking, interacting medicines, formulation, dose, disease severity, and the therapeutic target. None of these variables should be replaced by a constitutional inference.

Ayurvedic Personalization Extends Beyond Genomics

Ayurvedic individualization is broader than assigning one of three dosha labels. The physician examines the disorder, the patient’s present dosha and tissue state, digestive and assimilative capacity, strength, adaptation to diet and habits, mental resilience, age, habitat, season, and prior response to treatment. This is a clinical framework for matching the intensity and form of therapy to the person’s condition.

Constitution Does Not Dictate a Universal Dose

Classical reasoning permits mild, moderate, or stronger treatment according to the patient’s strength, disease strength, digestive capacity, age, and suitability. It does not support a universal rule that every Vata person must receive a low dose, every Pitta person must receive hepatotoxicity monitoring, or every Kapha person clears lipophilic medicines slowly. Those claims require medicine-specific clinical measurements.

Medicine, Preparation, Vehicle, and Timing

Ayurvedic prescribing distinguishes the medicinal substance from its preparation, dose, timing, route, and anupana, the accompanying vehicle. These choices are made in relation to the patient and disorder. They should not be converted into untested CYP, HLA, lipid-metabolism, or insulin-signalling claims merely because a traditional characteristic appears conceptually similar to a modern biomedical pathway.

Responsible Integration in Clinical Practice

Ayurveda and pharmacogenomics can be used together when each remains within its validated scope. Ayurvedic assessment can contribute a structured account of constitution, current imbalance, digestion, diet, routines, tolerance, and treatment preferences. Pharmacogenomics can answer selected questions about defined genetic variants and medicines.

A Safe Clinical Sequence

A practical integrative sequence begins with diagnosis and medication review, uses pharmacogenetic testing when supported by a recognized guideline, and adds qualified Ayurvedic assessment without treating Prakriti as a laboratory result.

1. Confirm the diagnosis, treatment indication, current medicines, allergies, organ function, and previous adverse reactions.
2. Identify whether an established gene-drug guideline applies to the medicine being considered.
3. Order a validated genetic test when its result is likely to affect prescribing or monitoring.
4. Assess Prakriti and Vikriti through a trained Ayurvedic practitioner as part of the broader clinical picture.
5. Review herbs, supplements, formulations, and dietary practices for interactions and product-quality concerns.
6. Monitor symptoms, laboratory values, efficacy, and adverse effects rather than assuming a response from constitution.

Herb-Drug Safety

Herbal products can alter absorption, sedation, blood pressure, glucose control, coagulation, or the activity of drug-metabolizing enzymes and transporters. Risks also depend on botanical identity, processing, contamination, dose, and the other ingredients in a formulation. Anyone taking prescription medicines should discuss Ayurvedic products with a qualified Ayurvedic practitioner and the prescribing healthcare professional, especially before surgery, during pregnancy, or when using anticoagulants, antiepileptics, immunosuppressants, or medicines with a narrow therapeutic range.

Limitations of the Current Evidence

Most molecular Prakriti studies have used small, highly selected groups representing relatively clear single-dosha phenotypes. Several enrolled only men or restricted participants to narrow age ranges. Such selection may help detect biological contrasts, but it represents only part of clinical practice, where dual-dosha constitutions and changing disease states are common.

Assessment methods also vary. A 2025 critical review identified 64 distinct Prakriti-assessment instruments, while only 20 had undergone some form of validation and none satisfied the review’s complete validation framework. Differences in questionnaires, examiner judgment, scoring rules, language, and thresholds make independent comparison and replication difficult.

Many studies are cross-sectional and examine numerous molecular variables simultaneously. Their findings require correction for multiple comparisons, replication in independent cohorts, appropriate ancestry controls, transparent preregistration, and confirmation with clinically meaningful outcomes. A molecular difference between groups is not equivalent to improved efficacy, reduced toxicity, or a validated prescribing recommendation.

Future Directions for Ayurgenomics

Future studies should use multicentre recruitment, standardized and independently tested constitution assessment, diverse ancestry groups, adequate representation of women and mixed constitutions, blinded phenotype assignment, and prespecified statistical plans. Replication cohorts should be included before a molecular marker is described as characteristic of a Prakriti group.

Drug-response studies should measure actual pharmacokinetic or clinical endpoints: drug and metabolite concentrations, treatment success, adverse reactions, laboratory toxicity, and validated patient outcomes. Prakriti-stratified findings should then be compared with direct genotyping and ordinary clinical predictors to determine whether constitutional assessment adds useful information beyond established practice.

Genomics, transcriptomics, epigenomics, proteomics, metabolomics, and microbiome analysis may help characterize biological diversity within and between constitutional groups. These methods are most informative when they test clearly defined hypotheses rather than assigning a single gene, enzyme, immune pathway, or disease tendency to an entire dosha.

Conclusion

Prakriti is an authentic Ayurvedic framework for understanding constitutional variation and tailoring clinical assessment. Human studies have reported associations involving HLA-DRB1 alleles, blood gene-expression profiles, CYP2C19 genotypes, DNA methylation, and genome-wide variants. The studies do not establish that dosha constitution can predict an individual’s response to conventional drugs or replace direct pharmacogenetic testing.

The most responsible integration is complementary: use Prakriti and Vikriti within a complete Ayurvedic examination, and use genotype-based recommendations only for gene-drug relationships supported by validated testing and clinical guidance. Prescription doses should never be started, stopped, or changed on the basis of dosha constitution without consultation with the prescribing healthcare professional.

This article is for educational purposes. Prakriti assessment, pharmacogenetic interpretation, herbal prescribing, and changes to conventional medication should be undertaken with appropriately qualified Ayurvedic and medical practitioners.

References

1. Charaka Samhita — Deha prakriti
2. Charaka Samhita — Rogabhishagjitiya Vimana
3. Frontiersin (frontiersin.org)
4. Classification of human population based on HLA gene polymorphism and the concept of Prakriti in Ayurveda (2005), PubMed
5. Link (link.springer.com)
6. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda (2008), PubMed
7. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
8. Link (link.springer.com)
9. Nature (nature.com)
10. Genome-wide analysis correlates Ayurveda Prakriti (2015), PubMed
11. A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy (2017), PubMed
12. Clinpgx (clinpgx.org)
13. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (2021), PubMed
14. Clinpgx (clinpgx.org)
15. Clinpgx (clinpgx.org)
16. Ayurgenomics for stratified medicine: TRISUTRA consortium initiative across ethnically and geographically diverse Indian populations (2017), PubMed
17. Recapitulation of Ayurveda constitution types by machine learning of phenotypic traits (2017), PubMed
18. Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift (2015), PubMed
19. Frontiersin (frontiersin.org)
20. Whole Exome Sequencing in Healthy Individuals of Extreme Constitution Types Reveals Differential Disease Risk: A Novel Approach towards Predictive Medicine (2022), PubMed
21. EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda (2010), PubMed

Most of this work has used 16S ribosomal RNA gene sequencing, which estimates the bacterial composition of a sample by analysing selected genetic regions. The method is useful for comparing microbial communities, but its taxonomic and functional resolution is limited. Results are also influenced by diet, geography, age, sex, medication exposure, stool collection, sequencing platform, and statistical method. These factors are especially important when interpreting constitution-based comparisons.

Prakriti in the Classical Ayurvedic Framework

In Ayurveda, deha-prakriti is the constitutional pattern expressed through the relative predominance of Vata, Pitta, and Kapha. Classical descriptions assess stable physical, physiological, and psychological characteristics rather than relying on a single symptom or questionnaire score. Charaka Samhita discusses constitutional examination in Vimana Sthana, while Sushruta Samhita and Ashtanga Hridaya also describe the characteristic features of dosha-predominant constitutions.

The classical framework is broader than the three labels commonly used in microbiome papers. It includes Vata-, Pitta-, and Kapha-predominant constitutions, three dual-dosha combinations, and a constitution in which the doshas are comparatively balanced. Many modern studies deliberately recruit people with strongly expressed or “extreme” single-dosha phenotypes because these groups are easier to compare statistically. Their findings therefore cannot automatically be applied to every person assessed in ordinary Ayurvedic practice.

Prakriti is also not equivalent to a medical diagnosis. It is used in Ayurveda as one element of individualized assessment alongside age, digestive capacity, strength, habitat, season, habits, current dosha disturbance, and the nature and stage of illness. A constitutional classification by itself does not diagnose irritable bowel syndrome, inflammatory bowel disease, obesity, diabetes, or metabolic syndrome.

What Human Microbiome Investigations Have Reported

The available studies differ substantially in sample size, recruitment, phenotype assessment, body site, analytical pipeline, and statistical approach. Their common finding is not that the three Prakriti groups possess completely separate microbial ecosystems, but that a broadly shared microbiome may contain taxa whose relative abundance differs between selected groups.

The 2021 investigation is the largest of these reports, but its results do not support the claim that every Vata, Pitta, and Kapha sample formed a clean, non-overlapping cluster. The authors identified a shared core microbiome and group-associated taxa. Twenty-one operational taxonomic units described as unique to a Prakriti group occurred in no more than four samples each, illustrating the difference between an exploratory association and a dependable population biomarker.

Why a Firmicutes-to-Bacteroidetes Table Is Misleading

A fixed table assigning high microbial diversity to Pitta, a high Bacteroidetes proportion to Vata, and a high Firmicutes-to-Bacteroidetes ratio to Kapha is not supported across the published cohorts. The 2018 investigation described Firmicutes and Bacteroidetes as major phyla with a similar overall pattern among the three groups, while later analyses emphasized subtler taxonomic or predicted functional differences.

The Firmicutes-to-Bacteroidetes ratio is itself an unreliable stand-alone marker of obesity or gut health. Human obesity studies have reported inconsistent results, partly because each phylum contains many organisms with different biological functions and because laboratory and population variables strongly affect the calculated ratio. It should therefore not be used to diagnose Kapha constitution, metabolic syndrome, microbial imbalance, or treatment need.

The available Prakriti cohorts consisted mainly of healthy participants. Their taxonomic differences cannot be converted into claims that Vata individuals are predisposed to irritable bowel symptoms, Pitta individuals to inflammatory gastrointestinal disease, or Kapha individuals to metabolic syndrome. Such associations require prospective clinical cohorts in which diagnoses, diet, medication, body composition, and other confounders are measured directly.

Host Constitution, Genetics, and Possible Biological Pathways

Earlier Ayurgenomics investigations reported gene-expression, biochemical, and genetic associations among carefully selected extreme Prakriti groups. A 2008 study examined whole-genome expression and biochemical variables, and a 2015 genome-wide study reported single-nucleotide polymorphisms whose frequencies differed among selected Vata, Pitta, and Kapha groups. These studies support examining Prakriti as a multidimensional phenotype, but they do not make dosha classification genetically deterministic or establish it as a substitute for clinical laboratory testing.

Several biological pathways could be investigated when studying host phenotype and microbial ecology. Diet, intestinal transit, bile acids, gastric conditions, mucosal secretions, immune activity, sleep, physical activity, and medication use can all influence microbial composition. Prakriti assessment may capture combinations of traits that co-vary with some of these factors. Demonstrating that a Prakriti-associated host feature directly creates a microbial pattern would, however, require longitudinal studies and controlled mechanistic experiments rather than cross-sectional stool sampling alone.

Agni and Microbial Composition Are Not Interchangeable Concepts

Ayurveda uses Agni to describe the functional capacity involved in digestion, transformation, and metabolism. Classical interpretation recognizes four principal digestive patterns: sama agni, a balanced pattern; vishama agni, an irregular pattern associated with Vata predominance; tikshna agni, an intense pattern associated with Pitta predominance; and manda agni, a slower pattern associated with Kapha predominance.

These are clinical Ayurvedic categories, not direct measurements of bacterial diversity, intestinal transit time, gastric acid, calorie expenditure, or a phylum ratio. A person with Kapha Prakriti does not necessarily have manda agni at every stage of life, and a person with Pitta Prakriti does not necessarily have persistently intense digestion. Current dosha state, food intake, season, illness, age, sleep, and treatment may alter digestive function.

The comparison between Agni and the microbiome can be useful as a research question because both frameworks place importance on diet and digestion. The 2020 paper associated with PMID 32932766 discusses this relationship as a review of modern and Ayurvedic perspectives; it was not an intervention trial demonstrating that Prakriti-specific dietary advice creates a defined microbial community.

Triphala and Direct Microbiome Research

Triphala Churna is an official Ayurvedic formulation consisting of equal parts of the powdered fruits of Haritaki (Terminalia chebula), Bibhitaka or Bibhitaki (Terminalia bellirica), and Amalaki (Phyllanthus emblica, also known by the synonym Emblica officinalis). This composition is listed in the Ayurvedic Formulary of India. The identity and quality standards of its individual ingredients are addressed in official Ayurvedic pharmacopoeial publications.

An in-vitro investigation using anaerobic human fecal cultures found that Triphala altered the experimental microbial community and increased the relative abundance of certain Bifidobacterium, Lactobacillus, and butyrate-producing organisms. Because the work was performed in laboratory cultures rather than as a controlled clinical microbiome trial, it establishes prebiotic potential under the tested conditions, not a guaranteed effect in the human intestine.

A universal daily dose of three to five grams cannot be presented as the standard microbiome dose. Ayurvedic prescribing considers formulation, indication, digestive capacity, age, strength, accompanying substances, concurrent medicines, and treatment duration. Extracts, powders, tablets, and products sold under the same name may also differ substantially in composition and concentration.

Panchakarma, Herbs, and Dietary Reviews

Panchakarma is a group of clinician-directed Ayurvedic procedures rather than a generic two-week “detox.” The 2024 publication identified by PMID 38401105 is a narrative review. It notes that virechana and basti have been examined in a small number of microbiome-related reports, while the available human literature is too limited and heterogeneous to define a reproducible Panchakarma microbiome outcome. It did not test Ashwagandha, Brahmi, and Tulsi together as a clinical treatment for stress-induced microbial imbalance, and it did not establish the stated extract doses as microbiome therapy.

The article identified by PMCID PMC10468021 is likewise a review, not a 2023 clinical intervention. It discusses Ayurvedic diet and lifestyle concepts, fiber-rich foods, plant polyphenols, and possible microbiome pathways in relation to type 2 diabetes. It does not demonstrate that a Prakriti-specific diet produced measured microbial changes or improved diabetes outcomes in a controlled participant group.

Traditional dietary qualities such as warm, unctuous, light, dry, bitter, pungent, or astringent remain part of individualized Ayurvedic dietetics. Assigning each quality a predetermined effect on bile acids, intestinal transit, Firmicutes abundance, or inflammatory signalling goes beyond the available clinical data. Dietary care for diabetes, inflammatory bowel disease, unexplained weight change, or persistent digestive symptoms should remain coordinated with appropriate medical diagnosis and monitoring.

A Responsible Research Agenda

The next stage of this field requires reproducible Prakriti assessment, inclusion of dual-dosha constitutions, multicentre recruitment, detailed dietary and medication records, and cohorts representing different regions and ethnic backgrounds. Repeated sampling is needed because one stool specimen provides only a time-limited view of a changing ecosystem.

Shotgun metagenomic sequencing could identify microbial genes and species more directly than 16S-based functional prediction. Metabolomics could measure products such as short-chain fatty acids and bile-acid derivatives, while carefully designed intervention trials could test whether a defined diet or authenticated formulation produces a clinically meaningful effect. Analyses should be preregistered and replicated in independent populations before microbial features are used for constitution assessment or treatment selection.

Longitudinal birth cohorts could also examine when constitution-associated traits and microbial communities begin to co-vary. Such studies would need serial infant sampling, parental and childhood dietary records, medication and delivery data, environmental measures, and constitution assessment performed with methods appropriate to age. Until that work exists, developmental explanations remain hypotheses rather than established Ayurvedic-microbiome mechanisms.

Safety note: Prakriti assessment, herbal prescribing, virechana, basti, and other Panchakarma procedures should be supervised by a qualified Ayurvedic practitioner. People who are pregnant, have a chronic illness, take prescription medicines, or have persistent gastrointestinal symptoms should also consult an appropriate healthcare provider. Ayurvedic products and microbiome tests must not replace indicated diagnostic testing or established medical treatment.

Practical Interpretation

Prakriti-microbiome research has identified group-level microbial associations worthy of further investigation. Its strongest verified message is that healthy Prakriti-classified participants share much of their gut microbiome while displaying some cohort-dependent differences in particular taxa. It does not yet justify fixed microbial profiles for Vata, Pitta, and Kapha, disease predictions based on constitution, or self-treatment intended to “correct” a presumed microbiome type.

Ayurveda contributes a detailed tradition of individualized assessment centred on constitution, current imbalance, digestion, diet, behaviour, and environment. Microbiome science contributes methods for measuring one part of the biological ecosystem involved in digestion and health. Their productive meeting point lies in carefully controlled, transparent research—not in treating preliminary associations as completed validation.

References

1. Jaims (jaims.in)
2. Charaka Samhita — Agni
3. Frontiersin (frontiersin.org)
4. Understanding the association between the human gut, oral and skin microbiome and the Ayurvedic concept of prakriti (2019), PubMed
5. Comparative gut microbiome analysis of the Prakriti and Sasang systems reveals functional level similarities in constitutionally similar classes (2020), PubMed Central
6. Exploring the signature gut and oral microbiome in individuals of specific Ayurveda prakriti (2021), PubMed
7. Ias (ias.ac.in)
8. Western Indian Rural Gut Microbial Diversity in Extreme Prakriti Endo-Phenotypes Reveals Signature Microbes (2018), PubMed Central
9. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? (2020), PubMed Central
10. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda (2008), PubMed
11. Genome-wide analysis correlates Ayurveda Prakriti (2015), PubMed
12. The Microbiome in Health and Disease from the Perspective of Modern Medicine and Ayurveda (2020), PubMed
13. Ayurvedic Pharmacopoeia of India
14. Prebiotic Potential of Herbal Medicines Used in Digestive Health and Disease (2018), PubMed
15. Ayurvedic Therapies to Target the Microbiome: Evidence and Possibilities (2024), PubMed
16. Modulation of gut microbiota with Ayurveda diet and lifestyle: A review on its possible way to treat type 2 diabetes (2022), PubMed Central
17. NCCIH

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.